5.3.5. non-ablative techniques. 5.3.5.1. prostatic urethral lift mechanism action: prostatic urethral lift (pul) minimally invasive approach local general anaesthesia. encroaching lateral lobes compressed small permanent suture-based implants delivered cystoscopic guidance resulting opening prostatic urethra leaving continuous anterior channel prostatic fossa. efficacy: several reports shown pul achieves significant improvement ipss (-39% -52%), qmax (+32% +59%) qol (-48% -53%) [542-547]. meta-analysis retrospective prospective trials, pooled estimates showed overall improvement following pul, including ipss, qmax, qol . cochrane review sham rct rct turp concluded pul appears less effective turp improving urological symptoms (ipss, qmax) short- long term, qol outcomes may similar . prostatic urethral lift evaluated vs. sham multicentre study one three five years follow-up treated cohort. improvements ipss, qol, qmax durable improvement rates 36%, 50%, 44% 60-month follow-up, respectively . network meta-analysis included outcome data three six months follow-up concluded improvement ipss similarly high turp pul. objective outcomes (pvr qmax) improved greatest extent turp, less improvement pul . retrospective observational study 1,413 consecutive patients north america australia split patients still voiding (group a) retention (group b). results group comparable results clinical trials 165 patients group b 69% catheter free five days, 83% one month 89% study end . tolerability safety: common complications reported post-operatively included haematuria (16-63%), dysuria (25-58%), pelvic pain (5-17.9%), urgency (7.1-10%), transient incontinence (3.6-16%), uti (2.9-11%) . symptoms mild-to-moderate severity resolved within two four weeks procedure. rct comparing pul turp, surgical recovery measured using validated instrument. found recovery pul rapid extensive first three six months . sr meta-analysis found sexual function regard erectile ejaculatory function remained stable improved slightly 24-month follow-up . rct comparing pul turp, pul resulted superior quality recovery ejaculatory function preservation. ejaculatory function bother scores change significantly either treatment arm . sr surgical re-interventions eleven studies (2,016 patients), among turp/laser (51%), repeat pul (32.7%) device explant (19.6%) common, revealed annual rate surgical re-intervention 6% per year (95% ci: 3.0-8.9) . re-treatment rate 13.6% five years multicentre study comparing pul vs. sham . practical considerations: limited data treating patients obstructed/protruding middle lobe . effectiveness large prostate glands shown yet. long-term studies needed evaluate duration effect comparison techniques. summary evidenceleprostatic urethral lift improves ipss, qmax qol; improvements inferior turp 24 months.1bprostatic urethral lift low incidence sexual side effects.1bpatients informed long-term effects, including risk retreatment, evaluated.4 recommendationstrength ratingoffer prostatic urethral lift (urolift®) men luts interested preserving ejaculatory function, prostates < 70 ml middle lobe.strong 5.3.5.2. intra-prostatic injections mechanism action: various substances injected directly prostate order improve luts including botulinum toxin-a (bont-a), fexapotide triflutate (nx-1207) prx302. primary mechanism action bont-a inhibition neurotransmitter release cholinergic neurons . mechanisms action injectables nx-1207 prx302 completely understood, experimental data suggest apoptosis-induced atrophy prostate drugs . efficacy: sr meta-analysis showed differences efficacy bont-a compared placebo concluded evidence clinical benefit medical practice . positive results phase ii-studies confirmed phase iii-trials prx302 . fexapotide triflutate (nx-1207) evaluated two multicentre placebo controlled double-blind randomised parallel group trials including total 995 patients mean follow-up 3.6 years, ipss change baseline significantly higher aur rate significantly reduced treatment arm. authors concluded nx-1207 effective transrectal injectable long-term treatment luts treated patients reduced need intervention . tolerability safety: sr meta-analysis showed low incidence rates procedure-related adverse events . two multicentre placebo controlled double-blind randomised parallel group trials long-term follow-up evaluating nx-1207 detected significant safety differences study arms . practical considerations: positive results prx 302 phase ii-studies confirmed phase iii-trials yet. nevertheless, rct evaluating transperineal intraprostatic bont-a injection vs. turp concluded ipss significantly decreased patients, non-significant difference arms bont-a injection significantly maintained erectile function compared turp twelve months . high-quality evidence reference techniques needed. summary evidenceleresults clinical trials shown clinical benefits bont-a compared placebo management luts due bpo.1aresults clinical trials shown clinical benefits nx-1207 compared placebo management luts due bpo.1b recommendationstrength ratingdo offer intraprostatic botulinum toxin-a injection treatment patients male luts.strong 5.3.5.3. non-ablative techniques investigation 5.3.5.3.1.(i)tind mechanism action: itind nitinol device composed three elongated struts anchoring leaflet. direct visualisation itind deployed inside prostate expanded configuration. intended mode action compress obstructive tissue expanded device, thereby exerting radial force leading ischaemic necrosis resulting turner warwick like incision. itind device left position five days removed outpatient setting standard urethroscopy. efficacy: single-arm, prospective study 32 patients three-year follow-up conducted evaluate feasibility safety procedure . change baseline ipss, qol qmax significant every follow-up . multicenter rct, 175 men randomised 2:1 itind sham procedures. patients assessed baseline, 45 days, three, twelve months postoperatively. total 78.6% patients itind arm showed reduction ≥ 3 points ipss, vs. 60% patients control arm three months. twelve months follow-up, itind group reported mean decrease 9.25 ipss, 1.9-point qol 3.52ml/s increase qmax compared baseline . prospective multicentre study, 81 patients enrolled treated second generation itind device. twelve-month follow-up, mean ipss decreased 22.5 8.8 qmax one month increased 7.3 14.7 ml/s twelve months . another network meta-analysis included outcome data three six months follow-up concluded ipss improvement lower itind compared turp. improvements objective outcomes (pvr qmax) also lower itind . tolerability safety: device reported well tolerated patients. four early complications (12.5%) recorded, including one case urinary retention (3.1%), one case transient incontinence due device displacement (3.1%), two cases infection (6.2%). complications recorded 36-month follow-up period . rct sham study adverse events typically mild transient, clavien-dindo grade 1 2 38.1% itind arm 17.5% control arm . new ejaculatory erectile dysfunction reported . prospective multicentre study, 81 patients enrolled treated second generation itind device. twelve-month period, two patients required medical therapy, two patients required turp, ten patients lost follow-up . practical considerations: randomised controlled trials comparing itind reference technique ongoing.